ALS clinical trials

Explore recruiting als clinical trials.

Recruiting als studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

ALS trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in participants with Amyotrophic Lateral Sclerosis

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Placebo-Controlled, Double-Blind, Single Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living With ALS

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)

Spain, Germany, Sweden, Ireland, Poland, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis

Denmark, France, Netherlands, Sweden, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)

Poland, Sweden, Czechia, Hungary, Bulgaria, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)

Czechia, Sweden, Italy, France, Bulgaria, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ALS trials by city

ALS in Toronto ALS in Vancouver ALS in Montreal ALS in Calgary ALS in Edmonton ALS in Ottawa ALS in Winnipeg ALS in Quebec City ALS in Hamilton ALS in Kitchener ALS in London ALS in Halifax ALS in New York ALS in Los Angeles ALS in Chicago ALS in Houston

Other conditions

Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Migraine Alzheimer's disease Parkinson's disease Multiple sclerosis Epilepsy Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia Depression Anxiety Bipolar disorder Schizophrenia PTSD OCD ADHD